Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Open Access
- 19 March 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 8 (9), 895-904
- https://doi.org/10.1016/s2213-2600(20)30033-3
Abstract
No abstract availableKeywords
Funding Information
- Experimental Cancer Medicine Centres (C22436/A25354)
This publication has 18 references indexed in Scilit:
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 2017
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2Journal of Clinical Oncology, 2013
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and CovariatesBiometrics, 2008
- Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?Journal of Thoracic Oncology, 2008
- Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancerBritish Journal of Cancer, 2001
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982